Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure.

Christiaens, Melissa; Collette, Sandra; Overgaard, Jens; Gregoire, Vincent; Kazmierska, Joanna; Castadot, Pierre; Giralt, Jordi; Grant, Warren; Tomsej, Milan; Bar-Deroma, Raquel; Monti, Angelo F; Hurkmans, Coen Wilhelm; Weber, Damien Charles (2017). Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure. Radiotherapy and oncology, 123(3), pp. 424-430. Elsevier 10.1016/j.radonc.2017.04.019

[img] Text
1-s2.0-S0167814017301603-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (981kB) | Request a copy

BACKGROUND AND PURPOSE The phase III EORTC 1219-DAHANCA 29 intergroup trial evaluates the influence of nimorazole in patients with locally advanced head and neck cancer when treated with accelerated radiotherapy (RT) in combination with chemotherapy. This article describes the results of the RT Benchmark Case (BC) performed before patient inclusion. MATERIALS AND METHODS The participating centers were asked to perform a 2-step BC, consisting of (1) a delineation and (2) a planning exercise according to the protocol guidelines. Submissions were prospectively centrally reviewed and feedback was given to the submitting centers. Sørensen-Dice similarity index (DSI) and the 95th percentile Hausdorff distance (HD) were retrospectively used to evaluate the agreement between the centers and the expert contours. RESULTS Fifty-four submissions (34 delineation and 20 planning exercises) from 19 centers were reviewed. Nine (47%) centers needed to perform the delineation step twice and three (16%) centers 3 times before receiving an approval. An increase in DSI-value and a decrease in HD, in particular for the prophylactic Clinical Target Volume (pCTV), could be found for the resubmitted cases. No unacceptable variations could be found for the planning exercise. CONCLUSIONS These BC-results highlight the need for effective and prospective RTQA in clinical trials. Even with clearly defined protocol guidelines, delineation and not planning remain the main reason for unacceptable protocol variations. The introduction of more objective quantitative analysis methods, such as the HD and DSI, in future trials might strengthen the evaluation by experts.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Weber, Damien Charles

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0167-8140

Publisher:

Elsevier

Language:

English

Submitter:

Beatrice Scheidegger

Date Deposited:

01 Mar 2018 13:01

Last Modified:

22 Oct 2019 19:00

Publisher DOI:

10.1016/j.radonc.2017.04.019

PubMed ID:

28478912

Uncontrolled Keywords:

Head and neck cancer Quality assurance Radiotherapy

BORIS DOI:

10.7892/boris.109277

URI:

https://boris.unibe.ch/id/eprint/109277

Actions (login required)

Edit item Edit item
Provide Feedback